Data gathered: June 2
Alternative Data for Sage Therapeutic
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 15,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | 1 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,876 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Sage Therapeutic
Sage Therapeutics, Inc., a biopharmaceutical company, develops and markets drugs to treat disorders of the central nervous system. The company is headquartered in Cambridge, Massachusetts.
| Price | $6.46 |
| Target Price | Sign up |
| Volume | 612,250 |
| Market Cap | $405M |
| Year Range | $4.78 - $8.66 |
| Dividend Yield | 0% |
| Analyst Rating | 11% buy |
| Industry | Biotechnology |
In the news
 |
Why Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report?May 29 - Yahoo |
|
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/YApril 30 - Yahoo |
|
Sage Therapeutics Inc (SAGE) Q1 2025 Earnings Call Highlights: Strong Demand for ZURZUVAE and ...April 29 - Yahoo |
 |
Sage Therapeutics, Inc. 2025 Q1 - Results - Earnings Call PresentationApril 29 - SeekingAlpha |
|
Sage Therapeutics, Inc. (SAGE) Q1 2025 Earnings Call TranscriptApril 29 - SeekingAlpha |
|
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue EstimatesApril 29 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 14M | 660,000 | 13M | -62M | -67M | -0.998 |
| Q4 '24 | 13M | 1.5M | 11M | -96M | -80M | -1.197 |
| Q3 '24 | 12M | 5.3M | 6.6M | -94M | -101M | -1.530 |
| Q2 '24 | 8.7M | 1.4M | 7.2M | -103M | -111M | -1.700 |
| Q1 '24 | 7.9M | 1.3M | 6.6M | -108M | -117M | -1.800 |
Insider Transactions View All
| Barrett Elizabeth filed to buy 3,000 shares at $18.6. August 11 '23 |
| Barrett Elizabeth filed to buy 1,000 shares at $50.5. May 11 '23 |
| JONAS JEFFREY M filed to sell 121,981 shares at $44.9. February 10 '23 |
| JONAS JEFFREY M filed to sell 125,819 shares at $44.5. February 10 '23 |
| Greene Barry E filed to buy 46,940 shares at $34.5. November 15 '22 |
Similar companies
Read more about Sage Therapeutic (SAGE) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Sage Therapeutic?
The Market Cap of Sage Therapeutic is $405M.
What is the current stock price of Sage Therapeutic?
Currently, the price of one share of Sage Therapeutic stock is $6.46.
How can I analyze the SAGE stock price chart for investment decisions?
The SAGE stock price chart above provides a comprehensive visual representation of Sage Therapeutic's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Sage Therapeutic shares. Our platform offers an up-to-date SAGE stock price chart, along with technical data analysis and alternative data insights.
Does SAGE offer dividends to its shareholders?
As of our latest update, Sage Therapeutic (SAGE) does not offer dividends to its shareholders. Investors interested in Sage Therapeutic should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Sage Therapeutic?
Some of the similar stocks of Sage Therapeutic are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.